Importantly, prolonged saturation of CD38 was witnessed in clinical setting several weeks after termination of daratumumab treatment, underscoring the necessity of tailoring the first dose to cancer-binding capacity for efficient prolonged TRT (44). The gene discussed is CD38; the disease is cancer.